Belatacept

Belatacept

Clinical data
Trade names	Nulojix
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a606016
Licence data	US FDA:link
Pregnancy cat.	C(US)
Legal status	℞-only (US)
Routes	Intravenous
Identifiers
ATC code	L04AA28
UNII	E3B2GI648A^Y
Chemical data
Formula	?
N(what is this?) (verify)

Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,^[1] which is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.^[2]

References

^ "Healthvalue.net: CTLA-4 Strategies". http://www.healthvalue.net/ctlaigenglish.html. Retrieved 2008-10-24.
^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm. Retrieved 2011-06-16.

Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine • Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide • Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus • Ciclosporin • Pimecrolimus Abetimus • Gusperimus

TNF-α inhibitor	Thalidomide • Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus • Deforolimus • Everolimus • Temsirolimus • Umirolimus • Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) • TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) • Interleukin 5 (Mepolizumab) • Immunoglobulin E (Omalizumab) • BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab, Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Gomiliximab, Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab) BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab, Cedelizumab, Fontolizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

Polyclonal

Anti-thymocyte globulin • Anti-lymphocyte globulin

-cept (Fusion)

CTLA-4 (Abatacept, Belatacept) • TNF inhibitor (Etanercept, Pegsunercept) • Aflibercept • Alefacept • Rilonacept

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)